WO2004074277A1 - N-アリール又はn-ヘテロアリールピペラジン誘導体及びそれを含有する医薬 - Google Patents
N-アリール又はn-ヘテロアリールピペラジン誘導体及びそれを含有する医薬 Download PDFInfo
- Publication number
- WO2004074277A1 WO2004074277A1 PCT/JP2004/001052 JP2004001052W WO2004074277A1 WO 2004074277 A1 WO2004074277 A1 WO 2004074277A1 JP 2004001052 W JP2004001052 W JP 2004001052W WO 2004074277 A1 WO2004074277 A1 WO 2004074277A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- compound
- alkoxy
- aryl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 208000003251 Pruritus Diseases 0.000 claims abstract description 6
- 206010011224 Cough Diseases 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 208000006673 asthma Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 230000036407 pain Effects 0.000 claims abstract description 5
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 4
- 208000017520 skin disease Diseases 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 133
- -1 Okiso group Chemical group 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000000565 sulfonamide group Chemical group 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 7
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 206010013990 dysuria Diseases 0.000 claims description 3
- 150000004885 piperazines Chemical class 0.000 claims description 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000005111 carboxyalkoxy group Chemical group 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 6
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000028938 Urination disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 45
- 238000000034 method Methods 0.000 description 28
- 239000003921 oil Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- 229910001868 water Inorganic materials 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- 206010038678 Respiratory depression Diseases 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108020001588 κ-opioid receptors Proteins 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
- OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 description 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MSYLETHDEIJMAF-UHFFFAOYSA-N 2,2-diphenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1=CC=CC=C1 MSYLETHDEIJMAF-UHFFFAOYSA-N 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical class C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GEPCQEJJOSFVEL-UHFFFAOYSA-N C1C=C(C=CC1(C2=CC=CC=C2)O)C3=CC=CC=N3 Chemical class C1C=C(C=CC1(C2=CC=CC=C2)O)C3=CC=CC=N3 GEPCQEJJOSFVEL-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QGJJOACVGVBTHP-UHFFFAOYSA-N ethoxy-(2-ethoxy-2-oxoethyl)phosphinic acid Chemical compound CCOC(=O)CP(O)(=O)OCC QGJJOACVGVBTHP-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- JOJPJLHRMGPDPV-LZQROVCBSA-N nor-binaltorphimine dihydrochloride Chemical compound Cl.Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 JOJPJLHRMGPDPV-LZQROVCBSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- N-aryl or N-heteroarylbiperazine derivatives and pharmaceuticals containing them
- the present invention relates to an N-aryl or N-heteroarylbiperazine derivative or a salt thereof having a mono-obioid receptor action, and a medicament containing the same.
- the present invention provides a gastrointestinal tract for pain, inflammation, arthritis, cough, asthma, dysuria, diarrhea, etc., which has excellent fc-receptor action and does not show side effects such as drug dependence and respiratory depression.
- An object of the present invention is to provide a compound that is excellent in preventing and / or treating dyskinesia, dyspepsia, or pruritus or a skin disease. Disclosure of the invention
- X represents a phenyl group which may have a substituent
- Y represents a hydrogen atom or a phenyl group which may have a substituent
- R 1 and R 2 are the same or different
- Z represents a force representing a C w alkyl group which may have a substituent or a 4- to 6-membered nitrogen-containing heterocyclic ring which may have a substituent together with an adjacent nitrogen atom
- C 6 — 2 which may have a substituent.
- a heteroaryl group which may have an aryl group or a substituent;
- the present invention also provides the following general formula (II):
- R 5 is a hydrogen atom or a C 7 _ 26 ⁇ aralkyl group; wherein, X, Y, R 1 and R 2 are as defined above. And a salt thereof.
- the N-aryl or N-heteroarylbiperazine derivative of the present invention is a compound represented by the above general formula (I), wherein a substituent which the phenyl group represented by X may have is a halogen atom , halogeno alkyl group, alkyl group, 6 ⁇ Norekokishi group, hydroxy group, amino group, Shiano group, Arukanoinore group, Kanoreba sulfamoyl group, a carboxyl group, a carboxy alkyl group, Arukanoiruoki And a nitro group, a sulfonamide group, a Cw alkylsulfonyl group and the like.
- a substituent which the phenyl group represented by X may have is a halogen atom , halogeno alkyl group, alkyl group, 6 ⁇ Norekokishi group, hydroxy group, amino group, Shiano group, Arukanoinore group,
- the alkyl in the halogeno C alkyl group, the alkyl group, the carboxy Cw alkyl group and the alkylsulfonyl group means that the straight-chain alkyl of Cw includes methyl, ethyl, n-propyl, n-butyl and the like.
- Examples of the branched alkyl include isopropynole, isobutyl, sec-butyl, tert-butyl and the like.
- Examples of the halogeno- 6 alkyl group include a trifluoromethyl group, a difluoromethyl group, a monofluoromethyl group, a trichloromethyl group, a dichloromethyl group, a monochloromethyl group, and the like.
- Examples of the carboxyalkyl group include a carboxymethyl group, and a sulfoxyl group.
- Examples of the CM alkylsulfonyl group include a methylsulfonyl group and an ethylsulfonyl group.
- Examples of the C ⁇ alkoxy group include a linear or branched alkoxy group of Specific examples include a methoxy group, an ethoxy group, an n-propoxy group, an isopropyloxy group, an n-butoxy group, an isobutyl group, a sec-butyl group, a tert-ptinole group, and the like.
- Examples of the C ⁇ aryl group in the C 1H5 group and the C 1-6 group include formyl, acetyl, propionyl, butyryl and the like.
- a halogen atom, a halogenated Cw alkyl group, a nitro group, a sulfonamide group or a Cw alkylsulfonyl group is preferred, and a halogen atom, a halogen atom, a halogenoalkyl group or a 6 alkylsulfonyl group is more preferred.
- a halogen atom, a trifluoromethyl group and a methylsulfoel group are particularly preferred.
- halogen atom a fluorine atom, a chlorine atom, a bromine atom or an iodine atom is preferable, and a fluorine atom or a chlorine atom is more preferable.
- the number of substituents is preferably from 1 to 5, more preferably from 1 to 3.
- the substituents that the phenyl group represented by Y may have include halogen atom, halogeno Cw alkyl group, alkyl group, alkoxy group, hydroxy group, amino group, cyano group, alkanoyl group, carbamoyl group, carboxyl group, carpo ⁇ C Cw alkyl group, Cw alkanoyloxy group, nitro group, sulfonamide group, C
- the number of the substituents is preferably 1 to 5, more preferably 1 to 3.
- Y is preferably a hydrogen atom or an unsubstituted fuunyl group.
- Examples of the ⁇ alkyl group of ⁇ include a Cw linear or branched alkyl group.
- examples of the linear alkyl group include a methyl group, an ethyl group, an n-propyl group, and an n-butyl group.
- examples of the branched alkyl group include an isopropyl group, an isobutyl group, and a sec_butyl group. And a tert-butyl group.
- examples of the substituent which these linear or branched alkyl groups may have include a nitrogen atom, a hydroxyl group and a carboxyl group.
- 4-6 membered nitrogen-containing saturated heterocycle for example Azechijin ring, pyrrolidine down ring, pin ⁇ lysine ring and the like.
- substituent which the ring is obtained having, human Dorokishi group, Okiso group, alkyl group, C 2 -.
- alkenyl group alkoxy group, hydroxy alkoxy, carboxy Cw alkoxy, carboxy ⁇ alkyl group, an alkoxycarbonyl alkylidene group A carboxyalkylidene group, a C w alkoxycarbonyl alkyl group, and a C w alkoxycarbonyl.
- Alkyl, alkoxy and alkanoyl in these substituents include the same as those described above.
- Examples of d- 6 alkylthio include methylthio, ethylthio, propylthio and the like.
- Examples of alkylidene include methylidene and ethylidene. The number of substituents is preferably one or two.
- C 6 — 2 denoted by Z.
- the aryl group include a phenyl group and a naphthyl group.
- the heteroaryl group represented by Z means a group composed of a 5- to 10-membered aromatic bicyclic ring containing one or more heteroatoms selected from N, O and S, and specifically, Pyrrolyl, furyl, chenyl, pyrazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinole, pyrazuryl, pyrimigel, benzopyrrolyl, benzofuranyl, benzo Chenyl group, benzopyrazolyl group, benzoisoxazolyl group, benzoisothiazolinole group, benzimidazolyl group, benzoxazolyl group, benzothiazolyl group, quinolyl group, isoquinolyl group, cinnolyl group
- the number of substituents is preferably 1 to 3, and the substitution position is not particularly limited.
- the C 6 "2. Ariru or heteroaryl group is obtained having substituents, halogen atom, halogenoalkyl group, ⁇ alkyl group, d_ 6 alkoxy group, hydroxy group, amino group, Shiano group, Al force Noiru group, a force Examples include a rubamoyl group, a carboxyl group, a carboxyalkyl group, a Cw alkanoyloxy group, a nitro group, a sulfonamide group, a sulfino 1-> alkyl group, etc.
- the alkyl, Cw alkoxy and alkanoyl groups are as described above.
- the number of substituents is preferably 1 to 3, and the substitution position is not particularly limited.
- N- Ariru or Teroari one Rubiperajin derivatives to N- of the present invention are those represented by the general formula (II), wherein, C 7 represented by R 5 - 26 ⁇ La alkyl group the, C 6 substituted or unsubstituted in the alkyl group - and the group 2 Q Ariru group is substitution.
- the substituents and the number thereof are the same as described above.
- C 7 - The 26 Ararukiru group specifically, a benzyl group, phenethyl group, Jifue two Rumechiru group, such as preparative Lihue El methyl group, and benzyl group are preferable among these.
- the salt of the N-aryl or N-heteroarylbiperazine derivative (I) of the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt.
- organic acid salts such as formate, acetate, trifluoroacetate, fumarate, maleate, tartrate, methanesulfonate, benzenesulfonate, P-toluenesulfonate; hydrochloride, bromide Inorganic salts such as hydrochloride, hydroiodide, sulfate, nitrate and phosphate.
- N-aryl or N-heteroarylpyrazine derivative (I) has an asymmetric carbon and therefore has stereoisomers, and all of these isomers are included in the present invention.
- the N-aryl or N-heteroarylpiperazine derivative (I) may exist as a solvate represented by a hydrate.
- the N-aryl or N-heteroarylbiperazine derivative (I) of the present invention can be produced, for example, by Production Methods 1 to 3. [Production method 1]
- W is a halogen atom
- X, Y, Z, for R 1 and R 2 are as defined in formula (I ⁇ );
- R 5 - 1 is C 7 - shows a 26 Ararukiru group.
- compound (1) and compound (2) synthesized according to the method described in J. Med. Chem. 36 (1993) 2075 are coupled to give compound (3), and compound (3) Is oxidized to a compound (4), the compound (4) is reacted with an amine (HNR 1 R 2 ), and then reduced to obtain a compound (5).
- the compound (6) obtained by dearalkylation of the compound (5) is reacted with various halogenoaryls (7) or halogenoheteroaryls (7) to obtain a compound (I).
- compound (1) has one asymmetric carbon, there are two kinds of optical isomers. However, according to the method described in the above-mentioned literature, two kinds of optical isomers can be produced separately. Hereinafter, each step will be described in detail.
- Compound (2) has the ability to purchase a commercially available reagent or a known method (for example, Chem. Ph. Rm. Bull. 33 (1985) 5245).
- the coupling between compound (1) and compound (2) can be carried out by converting compound (2) into the corresponding acid chloride and then reacting with compound (1), or by coupling compound (1) with compound (2).
- the reagent used for converting the compound (2) into the corresponding acid chloride include oxalyl chloride and thionyl chloride.
- suitable condensing agents include, for example, carbodildimidazole, 1-hydroxyl-2 (1H) -pyridone, 1-hydroxyl-1H-benzotriazonole, N-hydroxysuccinimide , Diphenylphosphoryl azide, 1-ethyl-3- (3-dimethylaminopropyl) 1- ⁇ -bodiimide hydride chloride, etc., and an appropriate base depending on the type of condensing agent, for example, triethylamine, pyridine
- the reaction is performed in the presence of an organic base such as
- the solvent used in these reactions is not particularly limited as long as it does not affect the reactions, and examples thereof include benzene, toluene, tetrahydrofuran, chloroform, dichloromethane, and N, N-dimethylhonoleamide.
- Oxidation of compound (3) can be carried out by Swan oxidation, Dess-Martin oxidation, or the like known to those skilled in the art, to obtain compound (4).
- the reaction of the compound (4) with an amine (HNI ⁇ R 2 ) and subsequent reduction can be carried out by the method described in J. Med. Chem. 36 (1993) 2075.
- the dearalkylation of compound (5) can usually be carried out by catalytic hydrogenation.
- Suitable examples of the catalyst used for catalytic hydrogenation include, for example, palladium-carbon, palladium-black, palladium catalyst such as palladium hydroxide, platinum oxide and platinum catalyst such as platinum-black, and Raney nickel, etc. Nickel catalysts and the like can be mentioned.
- the reaction is usually performed in the presence of a solvent, and the solvent is not particularly limited as long as it does not affect the reaction. For example, methanol, ethanol, tetrahydrofuran, dioxane, N, N-dimethylformamide and the like are used.
- the reaction temperature is not particularly limited, and may be usually performed at room temperature or under heating.
- halogenoaryl (a) and halogenoaryl respectively. It can be carried out according to the method described in Acc. Chem. Res. 31, 805-818 using a terroir (7).
- W in halogenoaryl (7) and halogenoheteroaryl (7) include, for example, chlorine, bromine, iodine and the like.
- W and R 5 - about 1 is as defined in Process 1;
- X, Y, ⁇ , for R 1 and R 2 are as defined in formula (I). ]
- the compound of the formula (I) can also be produced by this production method. That is, the compound (1) is further dearalkylated to give a compound (8), and an aryl group or a heteroaryl group is introduced into the compound (8) to give a compound (9). Compound (9) is coupled with compound (2) to give compound (10), oxidized (11), and further reacted with amine (HNRLRJ, followed by reduction to give compound of formula (I). (8) can be synthesized according to the method described in J. Med. Chem. 36 (1993) 2075. The aryl or heteroaryl group to the compound (8) can be synthesized by the same method as in Production method 1.
- the coupling between compound (9) and compound (2) can be carried out by converting compound (2) to the corresponding acid chloride and then reacting with compound (9), or Is reacted with compound (2) in the presence of a suitable condensing agent to obtain compound (10).
- a suitable condensing agent to obtain compound (10).
- the reagents, condensing agents, bases and reaction solvents used as necessary for conversion to the acid chloride to be used are the same as those described in Production Method 1.
- the reaction of the compound (11) obtained by oxidizing the compound (10) with an amine (HNI ⁇ R 2 ) can be carried out by the method described in J. Med. Chem. 36 (1993) 2075.
- Amine (HNI ⁇ R 2 ) can be produced by a known method, or can also be synthesized according to the following methods for producing an amine ( 1 ) to ( 3 ).
- Compound (1-2), compound (1-3), compound (1-4), compound (1-5) and compound (1-6) can be synthesized according to the present production method. That is, the compound (1-1) produced by the production method 1 or the production method 2 Compound (I one 2) obtained.
- Examples of the oxidation reaction include Swan oxidation and Dess-Martin oxidation.
- Compound (1-3) can be produced by reacting compound (1-2) with a Horner-Emmons refining reagent known to those skilled in the art.
- Compound (1_4) can be produced by hydrolyzing compound (1-3) under basic conditions. Examples of the base used include sodium hydroxide, potassium tert-butoxide and the like.
- the conversion of compound (1-3) to compound (I-15) can be carried out by a suitable reduction reaction, for example, reduction by catalytic hydrogenation in the presence of a catalyst.
- a suitable reduction reaction for example, reduction by catalytic hydrogenation in the presence of a catalyst.
- Suitable examples include, for example, palladium catalysts such as palladium-carbon, palladium-black, hydroxide palladium, platinum catalysts such as platinum oxide and platinum black, and nickel catalysts such as Raney nickel.
- Compound (I-16) can be produced by hydrolyzing compound (1-3) under basic conditions. Examples of the base used include sodium hydroxide and potassium tert-butoxide.
- the amine (HNRiR 2 ) used in production methods 1 to 3 can be produced by the following production methods 1 to 3.
- P represents a protecting group for amine
- Q represents a halogen atom or an R 4 -sulfonyloxy group (R 4 represents a lower alkyl group or a phenyl group substituted with a lower alkyl group.)
- compound (12) is reacted with compound (13) to react with compound (1).
- Compound (12) and compound (13) can be produced by a known method.
- the protecting group P include, for example, TW Greenand P. GM Wnts., Protective Grouin Or ganicc ⁇ ynthes ⁇ s, John Wi ley & Sons Inc., New York, 1999.
- Q in compound (13) include chlorine, bromine, iodine, mesyloxy group, and tosyloxy group. This reaction can be carried out in a suitable solvent in the presence of a base, and a phase transfer catalyst may be used depending on the type of compound (13).
- Examples of the solvent used include N, N-dimethylformamide, dimethylsulfoxide, methanol, ethanol, tetrahydrofuran, dioxane, and acetonitrile.
- examples of the base used include sodium hydroxide, hydroxylating water, sodium hydride, calcium hydride, sodium tert-butoxide, potassium tert-butoxide and the like.
- the reaction temperature is not particularly limited. Deprotection of compound (14) can be carried out by a general method.
- the compound (12) is mesylated to give a compound (16), and then the compound (16) is reacted with potassium thioacetate in N, N-dimethylformamide to form a thioacetate ( 1 7)
- the compound (17) is reacted with the compound (13) to give a compound (18).
- the compound is deprotected to give an amine (HNF ⁇ R 2 ) (19).
- the mesylation of the compound (12) can be carried out by a known method by using a mesyl chloride.
- the compound (18) was obtained by using the compound (13) and preparing the compound described in Tetrahedron Letter 40 (19999) 1101-1102. It can be manufactured according to the method.
- Examples of Q in the compound (13) include chlorine, bromine, iodine, a mesyloxy group, and a tosyloxy group.
- Deprotection of compound (18) can be performed by a general method, and compound (19) can be obtained.
- the compound (20) is reduced to a compound (21), and then the compound (22) is obtained using a Horner-Emmons refining reagent. Finally, the olefin is reduced at the same time as the removal of the benzyl group to give the amine (HNR ⁇ R 2 ) (23).
- Compound (20) can be synthesized according to the method described in Synthesesis 10 (1998) 1491-1495.
- the reduction of the compound (20) can be carried out, for example, by DI BALH reduction.
- the removal of the benzyl group and the reduction of olefins can be performed, for example, by catalytic hydrogenation of compound (22) .
- the catalyst, reaction solvent, and reaction temperature for catalytic hydrogenation are the same as those described in Production method 1. .
- Isolation and purification of the compound (I) of the present invention can be carried out by a conventional method, for example, washing, extraction, recrystallization, chromatography, and the like.
- conversion to salt can be carried out according to a conventional method.
- the racemic compound can be prepared by using an appropriate starting compound or by a general racemic resolution method [for example, by using a general optically active acid (tartaric acid, etc.)].
- the compound (I) of the present invention has an excellent fc-opioid receptor activity, as shown in the test examples described below, and has gastrointestinal motility disorders such as pain, inflammation, arthritis, cough, asthma, and diarrhea; It is useful as a medicament for preventing or treating pruritus or skin diseases.
- the compound (I) of the present invention When the compound (I) of the present invention is used as such a medicament, it is mixed with a solid or liquid carrier known in the art, and a pharmaceutical composition (pharmaceutical formulation) suitable for parenteral administration, oral administration or external administration is prepared. ) And it is sufficient.
- the pharmaceutical preparation include liquid preparations such as injections, inhalants, syrups and emulsions, solid preparations such as tablets, capsules and granules, external preparations such as ointments and suppositories.
- these preparations may optionally contain commonly used additives such as auxiliaries, stabilizers, wetting agents, emulsifiers, absorption promoters, surfactants and the like.
- additives include distilled water for injection, Ringer's solution, glucose, sucrose syrup, gelatin, edible oil, cocoa butter, magnesium stearate, and talc.
- the dose of the compound (I) of the present invention when used as a medicament varies depending on the administration method, the age, weight, and condition of the patient, but when administered orally to adult patients, 0.1 to 1000 mg per day. It is preferable that The compound (I) of the present invention can be used not only in humans but also in other mammals as veterinary medicine.
- Triethylamine (0.5 mL) was added to a solution of 3- (hydroxymethyl) -111-phenylbiperazi (0.1 g) in anhydrous tetrahydrofuran (20 mL), and diphenylacetylacetyl chloride (0.25 g) was stirred at room temperature. Was added little by little over 1 minute, and the mixture was further stirred at room temperature for 4 hours. Then, water was added to the reaction mixture, extracted with ethyl acetate, washed with water, dried over sodium sulfate and distilled off under reduced pressure. Next, this residue was dissolved in a mixed solvent of methanol (5 mL) and Z dioxane (5 mL), and further 1N aqueous sodium hydroxide solution was added.
- the reaction solution was concentrated under reduced pressure, water (10 mL) was added to the residue, the pH was adjusted to 5 to 6 with 2 ° / 0 aqueous solution of citric acid, and the mixture was extracted with chloroform. The solvent was concentrated under reduced pressure, and the residue was crystallized from ether. The title compound was obtained as pale yellow unstable powder (0.053 g). Yield: 75%.
- Test example 1 ⁇ opioid receptor affinity test
- test drug was obiooidagonist by using a selective / c-Obioid antagonist, nor-BNI (nor-Binaltorphimine dihydrochloride). Table 2 shows the test results.
- the compound (I) of the present invention has a / c-opioid receptor effect, and has gastrointestinal motility disorders such as pain, inflammation, arthritis, cough, asthma, dysuria, diarrhea, indigestion, or pruritus or skin It is useful as a medicament for preventing and / or treating diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005502674A JP4499034B2 (ja) | 2003-02-19 | 2004-02-03 | N−アリール又はn−ヘテロアリールピペラジン誘導体及びそれを含有する医薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-040587 | 2003-02-19 | ||
JP2003040587 | 2003-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004074277A1 true WO2004074277A1 (ja) | 2004-09-02 |
Family
ID=32905254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001052 WO2004074277A1 (ja) | 2003-02-19 | 2004-02-03 | N-アリール又はn-ヘテロアリールピペラジン誘導体及びそれを含有する医薬 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4499034B2 (ja) |
WO (1) | WO2004074277A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009044883A1 (ja) * | 2007-10-05 | 2009-04-09 | Toray Industries, Inc. | モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0343900A2 (en) * | 1988-05-23 | 1989-11-29 | Glaxo Group Limited | Piperazine compounds |
JPH03163067A (ja) * | 1989-08-11 | 1991-07-15 | Sankyo Co Ltd | アリール酢酸アミド誘導体 |
WO1997032857A1 (en) * | 1996-03-08 | 1997-09-12 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
-
2004
- 2004-02-03 JP JP2005502674A patent/JP4499034B2/ja not_active Expired - Lifetime
- 2004-02-03 WO PCT/JP2004/001052 patent/WO2004074277A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0343900A2 (en) * | 1988-05-23 | 1989-11-29 | Glaxo Group Limited | Piperazine compounds |
JPH03163067A (ja) * | 1989-08-11 | 1991-07-15 | Sankyo Co Ltd | アリール酢酸アミド誘導体 |
WO1997032857A1 (en) * | 1996-03-08 | 1997-09-12 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
Non-Patent Citations (1)
Title |
---|
NAYLOR A, ET AL: "A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-((dialkylamino)methyl)piperazines", JOURNAL OF MEDICAL CHEMISTRY, vol. 36, no. 15, 1993, pages 2075 - 2083, XP002920054 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009044883A1 (ja) * | 2007-10-05 | 2009-04-09 | Toray Industries, Inc. | モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 |
CN101848714A (zh) * | 2007-10-05 | 2010-09-29 | 东丽株式会社 | 以吗啡喃衍生物或其药理学上允许的酸加成盐为有效成分的皮肤性状改善治疗药 |
AU2008308005B2 (en) * | 2007-10-05 | 2012-06-07 | Toray Industries, Inc. | Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient |
CN101848714B (zh) * | 2007-10-05 | 2014-08-20 | 东丽株式会社 | 以吗啡喃衍生物或其药理学上允许的酸加成盐为有效成分的皮肤性状改善治疗药 |
JP5613417B2 (ja) * | 2007-10-05 | 2014-10-22 | 東レ株式会社 | モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 |
Also Published As
Publication number | Publication date |
---|---|
JP4499034B2 (ja) | 2010-07-07 |
JPWO2004074277A1 (ja) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3220266B2 (ja) | アザヘテロサイクリルメチル−クロマン | |
US7335670B2 (en) | Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics | |
JP4229701B2 (ja) | β−ラクタム化合物及びその製造方法並びにこれを含有する血清コレステロール低下剤 | |
CN110049984B (zh) | 苯基丙酸衍生物及其用途 | |
PL196510B1 (pl) | Pochodne amidowe, ich sole oraz środek farmaceutyczny zawierający takie pochodne lub ich sole | |
PL190310B1 (pl) | Pochodna monocyklicznego benzamidu 4-(aminometylo)piperydyny i sposób jej wytwarzania, kompozycja farmaceutyczna, pochodna 4-(aminometylo)piperydyny i pochodna kwasu p-aminobenzoesowego | |
WO2005095338A1 (ja) | アルコキシフェニルプロパン酸誘導体 | |
KR20040103973A (ko) | N-[페닐(피페리딘-2-일)메틸]벤즈아미드의 유도체, 그의제조 방법 및 치료법에서의 그의 용도 | |
AU2005213538A1 (en) | Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists | |
US20030176693A1 (en) | Diphenylalkylamine derivatives useful as opioid receptor agonists | |
EA003608B1 (ru) | 4-(аминометил)пиперидинбензамиды для лечения желудочно-кишечных расстройств | |
WO2003101964A1 (fr) | Derive piperidine, procede de production, et utilisation | |
KR20010006120A (ko) | 혈관 수축제로써의 인다졸 아마이드 화합물 | |
CA3217720A1 (en) | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | |
WO1996038415A1 (fr) | Nouveaux derives de l'acide 2-amino-3-phenylpropionique | |
JP2003517013A (ja) | フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物 | |
KR100245955B1 (ko) | 메타노안트라센화합물 | |
WO1996002503A1 (fr) | Nouveaux composes ayant un effet inhibant l'agregation plaquettaire | |
WO2022138888A1 (ja) | テトラヒドロキノリン誘導体及びその医薬用途 | |
TWI770841B (zh) | 作為組蛋白脫乙醯基酶6抑制劑之1,3,4-㗁二唑衍生物化合物及包含其的醫藥組合物 | |
JPH0354937B2 (ja) | ||
CS214796B2 (en) | Method of making the new derivatives of 4-amino-2-piperidinochinazoline | |
WO2004074277A1 (ja) | N-アリール又はn-ヘテロアリールピペラジン誘導体及びそれを含有する医薬 | |
WO1997034873A1 (fr) | Derives d'aminopyridine | |
EP1630159A1 (en) | 5-HT7 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005502674 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |